• Assay Selection Tool

BellBrook Labs

  • Products
    • Transcreener® HTS Assay Kits
      • Transcreener® ADP² Kinase Assay Kits
        • Transcreener® ADP2 Assay Kit – FP Readout
        • Transcreener® ADP2 Assay Kit – FI Readout
        • Transcreener® ADP2 Assay Kit – TR-FRET Readout
      • Transcreener® ADO CD73 Assay Kit
      • Transcreener® AMP²/GMP² Phosphodiesterase Assay Kits
        • Transcreener® AMP2/GMP2 FP Assay
        • Transcreener® AMP2/GMP2 Assay Kit – TR-FRET Readout
      • Transcreener® cGAMP cGAS Assay Kits
        • Transcreener® cGAMP Assay Kit – FP Readout
        • Transcreener® cGAMP Assay Kit – TR-FRET Readout
      • Transcreener dAMP Exonuclease Assay Kit
      • Transcreener® EPIGEN SAH Methyltransferase Assay Kit
      • Transcreener® GDP GTPase Assay Kits
        • Transcreener® GDP Assay Kit – FP Readout
        • Transcreener® GDP Assay Kit – FI Readout
        • Transcreener® GDP Assay Kit – TR-FRET Readout
      • Transcreener® UDP² Glycosyltransferase Assay Kits
        • Transcreener® UDP2 Assay Kit – FP Readout
        • Transcreener® UDP2 Assay Kit – FI Readout
        • Transcreener® UDP2 Assay Kit – TR-FRET Readout
      • Transcreener® 2-5A OAS Assay Kit
    • AptaFluor® HTS Assay Kits
      • AptaFluor® SAH Methyltransferase Assay Kit
    • Enzyme Assay Systems
      • TREX1 Assay System
    • Recombinant Enzymes
      • Human cGAS Enzyme
      • Mouse cGAS Enzyme
      • Human DDX3 Enzyme
      • Human OAS1 Enzyme
      • Human TREX1 Enzyme
    • Assay Plates
    • Ordering Information
  • Services
    • Assay Development Services
    • Lead Discovery Services
    • CD38 Assay Services
    • GTPase Profiling Services
    • ATPase Profiling Services
  • Assays by Target
    • Kinase Assays
      • ADK Assays – Application
      • AMPK Assays – Application
      • IKK-beta Assays – Application
      • IRAK4 Assays – Application
      • JAK1 Assays – Application
      • JAK3 Assays – Application
      • MAPK8 Assays – Application
      • PKR Assays – Application
      • RIPK1 Assays – Application
      • RIPK2 Assays – Application
      • TBK1 Assays – Application
    • GTPase Assays
      • GAP Assays – Application
      • GEF Assays – Application
      • KRAS Assays – Application
      • HRAS Assays – Application
      • NRAS Assays – Application
      • RRAS Assays – Application
      • Rac1 Assays – Application
      • RhoA Assays – Application
      • RhoC Assays – Application
      • Cdc42 Assays – Application
      • Ran Assays – Application
    • Methyltransferase Assays
      • EZH2 Assays – Application
      • G9a Assays – Application
      • SET7/9 Assays – Application
      • SET8 Assays – Application
      • PRMT1 Assays – Application
      • PRMT3 Assays – Application
      • PRMT4 Assay – Application
    • STING Pathway Assays
      • cGAS Assay Kits
      • ENPP1 Assays – Application
      • TREX1 Assay System
      • IKK-beta Assays – Application
      • TBK1 Assays – Application
    • Nucleotidase Assays
      • CD38 Assay Services
      • CD39 Assays – Application
      • CD73 Activity Assay Kits
    • Helicase / ATPase Assays
      • DDX3 Assays – Application
      • NSP13 Assays – Application
      • P97 Assays – Application
    • Glycosyltransferase Assays
      • Toxin B Assays – Application
      • GALNT2 Assays – Application
      • GALNT3 Assays – Application
      • BGalT1 Assays – Application
    • Phosphodiesterase Assays
      • PDE3 Assays – Application
      • PDE4 Assays – Application
      • PDE5 Assays – Application
      • PDE7 Assays – Application
    • Ligase and Synthetase Assays
      • SUMO E1 Assays – Application
      • Acyl CoA Synthetase Assays – Application
      • S-Acetyl CoA Synthetase Assays – Application
    • Exonuclease Assays
      • TREX1 Assay System
    • OAS Assays
      • OAS1 Assay Kits
    • Other Enzyme Assays
      • NUDT5 Assays – Application
  • Resources
    • Technical Manuals
    • Transcreener® Assays – Instrument Compatibility
    • Application Notes
    • Posters and Presentations
    • Publications
    • Transcreener® FAQ’s
    • Guides
      • Residence Time Guide
      • Hit Prioritization Guide
      • Kinases in Innate Immunity
  • Company
    • President’s Message
    • International Distributors
    • Careers
    • Downloads
    • Contact Us
  • Blog
  • MY CART
    No products in cart.

Fighting Infection’s Ghost

by Robyn Perrin / Wednesday, 15 June 2016 / Published in Emerging Targets

Aicardi–Goutières syndrome (AGS) is a rare and brutal genetic condition. Most infants born with the syndrome are asymptomatic at birth, but about 1 in 5 have enlarged spleen and liver, elevated liver enzymes in the blood, decreased platelet level, and abnormal neurological responses. Over the first year of life, things get much worse: episodes of severe brain dysfunction (encephalopathy), fevers but no infection, seizures. The infants’ growth slows (including brain and skull development, resulting in microcephaly), and developmental milestones that had been reached are lost. Signs of persistent inflammation occur throughout the body, and white blood cells and inflammatory markers accumulate in the cerebrospinal fluid.

STING2

These babies’ bodies are fighting a ghost of infection. Inflammation of the central nervous system happens while the body launches an all-out inflammatory assault…responding to pathogens that aren’t there.

The results are devastating. White matter in the brain deteriorates and brain tissue calcifies, causing profound intellectual disability. AGS patients experience impaired muscle function, causing muscle stiffness, involuntary muscle contractions in the arms, and muscular weakness in the torso. Nearly half of patients have painful, itchy skin lesions on their extremities and problems with vision, joints, and ulcers in the mouth. Most do not survive childhood, though some people with milder manifestations of AGS may live into adulthood.

Why does the body go into defensive overdrive during AGS, destroying itself in the process? Recent research out of the University of Edinburgh[1] shows that a mutation in Rnaseh2b causes accumulation of DNA:RNA hybrid molecules, which trigger the cGAS/STING innate immune system pathway. DNA:RNA hybrids occur during the normal course of transcription and DNA replication, and ribonucleotides are excised by the three-subunit RNase H2 complex. In individuals with AGS who have an A174T missense mutation in Rnaseh2b, a functional RNase H2 complex does not assemble, RNA:DNA hybrids are not processed properly, and the nucleic acid sensor cGAS is activated. Normally, cGAS acts in surveillance mode to detect cytosolic DNA that occurs during viral pathogen infection. During this process, cGAS produces the dinucleotide cyclic GMP‑AMP (cGAMP), which activates the STING receptor, leading to the expression of type I IFN‑stimulated genes and inflammation. It’s a helpful innate immune response under normal conditions, but the continual accumulation of DNA:RNA hybrids that form in people with AGS causes the cGAS/STING pathway to be constantly activated.

Animal models to study AGS, however, have been limited, as homozygous RNase H knockout mice are embryonic lethal. Researchers at the University of Edinburgh recently generated Rnaseh2bA174T/A174T knock-in mice as a subclinical model of disease, allowing detailed investigation into the molecular mechanism of AGS in this genetic context. Unlike the severe phenotypes seen in humans with the A174T mutation, the knock-in strain appear phenotypically normal, although interferon-stimulated gene transcript regulation occurred as it does in AGS patients. However, absence of phenotype had also been observed with mice deficient in two other loci that can cause AGS when disrupted, Samhd1 and Trex1.  Analyzing the Rnaseh2bA174T/A174T knock-in strain and mouse embryonic fibroblasts generated from breeding Rnaseh2b-/- with p53-/- mice, researchers confirmed that the inflammatory response requires cGAS and STING, and that the mutation causes reduced cellular ribonucleotide excision repair activity and increased DNA damage.

While therapeutic interventions for AGS are still on the horizon, relevant animal models are key to developing badly-needed therapeutic strategies for this and similar interferonopathies. The development of in vitro assays for probing the cGAS/STING pathway is also critical for progress.

Read more about the new Transcreener cGAMP cGAS Assay targeting the cGAS-STING pathway.

[1] Mackenzie KJ, et al. 2016. Ribonuclease H2 mutations induce a cGAS/STING-dependent innate immune response. EMBO J 35:831-844.

Tagged under: Transcreener cGAMP cGAS Assay

What you can read next

IKK Complex & Inflammation
IKK Complex, NF-kB, and Inflammation – An Intricate Relationship
Phosphodiesterase Inhibitors: Increasing Immunity and Improving Antitumor Therapies
Ubiquitin Ligase Assay Tool for Drug Discovery
Ubiquitin Ligase Assay: A Handy Tool for Drug Discovery

Categories

  • Company
  • Emerging Targets
  • Epigenetics
  • HTS Assays
  • Innate Immunity
  • Neurodegenerative Diseases
  • News
  • Products
  • Resources
  • Success Stories
  • Uncategorized

Recent Posts

  • PARP1 as a Hero vs Villain

    Is PARP1 a Hero or Villain?

    Not counting histones, PARP1 [Poly(ADP-ribose) ...
  • Ongoing Puzzle of c-SRC in Cancer Treatment

    Advancements in The Ongoing Puzzle to Understand c-SRC

    Nearly a half-century ago, sequences from the R...
  • SLAS 2023 Conference Exhibitor Announcement

    SLAS 2023 – HTS Assays and Discovery Services

    BellBrook Labs will exhibit and present posters...
  • BTK's Involved in Systemic lupus erythematosus

    The Challenging Search for BTK Inhibitors

    Bruton’s Tyrosine Kinase (BTK) is a 76kDa...
  • SARM1 Causes Axonal Death

    SARM1 Forefronts Research into Major Neurological Diseases

    SARM1 [Sterile alpha & toll/interleukin rec...

Archives

BellBrook Labs
5500 Nobel Drive, Suite 230
Madison, Wisconsin 53711 USA
(608) 443-2400

info@bellbrooklabs.com

 Copyright © 2023 BellBrook Labs | All Rights Reserved | Privacy Policy | Terms of Use | FCOI | Sitemap

TOP